According to a statement issued by the company, total revenues for the December quarter stood at Rs 685.13 crore up 134 per cent against Rs 293.45 crore during October-December quarter in FY 16.
"The revenue and profit growth for the company during the quarter was driven predominantly by the sales of Oseltamivir product in the US market and includes profit sharing from our marketing partner," the statement added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
